GLPG2665

GLPG2665 is a next-generation C2 corrector drug candidate developed for cystic fibrosis, specifically targeting the delta F508 (class II) mutation. As a CFTR modulator, it is designed to restore proper function to the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein in patient cells. GLPG2665 is part of a triple combination therapy with corrector GLPG2222 and potentiator GLPG1837, which together have shown up to six-fold greater chloride transport in vitro compared to Orkambi (ivacaftor/lumacaftor) in human bronchial epithelial cells homozygous for the F508del mutation. The drug is one of multiple C2 corrector series identified by Galapagos, each with unique and complementary mechanisms of action, and has entered pre-clinical development with planned Phase 1 studies[1][3][5][7][8][11][12].

Brand names

GLPG2665GLPG-2665GLPG 2665

Other names

GLPG2665GLPG-2665GLPG 2665